TABROS PHARMA (PVT). LTD.
Private pharmaceutical manufacturer · Karachi · Pakistan
Pakistan pharmaceutical manufacturer and marketer with a broad branded portfolio and dedicated pharmacovigilance and product-safety functions.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Legal / official name
- Tabros Pharma (Pvt.) Ltd.
- Company type
- Private pharmaceutical manufacturer
- Address
- Essa House, 32-1-C, Block-6, P.E.C.H.S., Karachi, Pakistan
- Website
- tabrospharma.com ↗
- Phone
- +92 21 34533416-8
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 88%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| RONIL | Ceftriaxone | 500 mg | Injection | VIAL | 021809 | PKR 501.27 | PKR 501.27/vial/unit | 54% above median |
| RONIL RA | Ceftriaxone | 1 G | Injection | VIAL | 021807 | PKR 985.26 | PKR 985.26/vial/unit | 64% above median |
| RONIL RA | Ceftriaxone | 1 G | Injection | VIAL | 021810 | PKR 880.84 | PKR 880.84/vial/unit | 47% above median |
| SCABRID | Permethrin | 5% | Cream | 30gm | 055452 | PKR 122.76 | PKR 4.09/g | Near median |
| SCABRID | Permethrin | 5% | Lotion | 120ML | 055453 | PKR 330.06 | PKR 2.75/mL | Near median |
| SCABRID | Permethrin | 5 % | Lotion | 60ML | 055453 | PKR 165.22 | PKR 2.75/mL | 5% above median |
| SCABRID | Permethrin | 5 % | Lotion | 240ML | 055453 | PKR 542.90 | PKR 2.26/mL | 14% below median |
| SIPZ | Sodium chloride | 3.5 g | Sachet | 20's | 088202 | PKR 438.79 | PKR 21.94/sachet | No comparator |
| SUINT | Ivermectin | 6 mg | Tablet | 10's | 073720 | PKR 489.34 | PKR 48.93/tablet | 10% below median |
| TABROFEN | Ibuprofen | 200 mg | Tablet | 500's | 006707 | PKR 1,178.59 | PKR 2.36/tablet | Near median |
| TABROFEN | Ibuprofen | 200 mg | Tablet | 30's | 006707 | PKR 70.42 | PKR 2.35/tablet | Near median |
| TABROFEN | Ibuprofen | 600 mg | Tablet | 24's | 015953 | PKR 242.67 | PKR 10.11/tablet | 62% above median |
| TABROGYL | Metronidazole | 200 mg | Tablet | 1000's | 005203 | PKR 1,061.52 | PKR 1.06/tablet | 51% below median |
| TABROGYL | Metronidazole | 200 mg | Tablet | 100's | 005203 | PKR 199.35 | PKR 1.99/tablet | 7% below median |
| TABROGYL | Metronidazole | 400 mg | Tablet | 100's | 011435 | PKR 352.21 | PKR 3.52/tablet | 19% above median |
| TABROGYL | Metronidazole | 200 mg/5 mL | Suspension | 60ml | 019257 | PKR 51.34 | PKR 0.86/mL | 7% below median |
| TABROPHAGE | Metformin | 500 mg | Tablet | 5x10's | 007718 | PKR 145.10 | PKR 2.90/tablet | 8% above median |
| Tivrox | Tranexamic acid | 250 mg/5 mL | Injection | 5x5ml | 014345 | PKR 274.62 | PKR 10.98/mL | 15% below median |
| Tivrox | Tranexamic acid | 250 mg/5 mL | Injection | 10x5ml | 014345 | PKR 560.10 | PKR 11.20/mL | 13% below median |
| Tivrox | Tranexamic acid | 500 mg/5 mL | Injection | 5x5ml | 014782 | PKR 513.00 | PKR 20.52/mL | 18% below median |
| Tivrox | Tranexamic acid | 500 mg/5 mL | Injection | 10x5ml | 014782 | PKR 1,046.95 | PKR 20.94/mL | 16% below median |
| TRYGIL | Nitroglycerin | 6.4 mg | Tablet | 30's | 107561 | PKR 373.67 | PKR 12.46/tablet | Near median |
| TRYGIL | Nitroglycerin | 2.6 mg | Tablet | 30's | 108577 | PKR 271.62 | PKR 9.05/tablet | Near median |
| TYMZ | Misoprostol | 200 mcg | Tablet | 10's | 088207 | PKR 199.44 | PKR 19.94/tablet | Near median |
| VIBRENTA | Sofosbuvir | 400 mg | Tablet | 28'S | 080177 | PKR 12,118.01 | PKR 432.79/tablet | Near median |
| VIBRENTA-VPT 400mg | Sofosbuvir + Velpatasvir | 400 mg + 100 mg | Tablet | 28'S | 089071 | PKR 19,945.06 | PKR 712.32/tablet | Near median |
| VIRENTA | Entecavir | 0.5 mg | Tablet | 3X10'S | 086874 | PKR 12,964.31 | PKR 432.14/tablet | 21% above median |
| VIZOR | Levofloxacin | 250 mg | Tablet | 10's | 032147 | PKR 480.11 | PKR 48.01/tablet | Near median |
| VIZOR | Levofloxacin | 500 MG | Tablet | 10's | 032148 | PKR 775.57 | PKR 77.56/tablet | Near median |
| Water for Injection | Water for Injection | 5 mL | Injection | 5ml x 100's | 010588 | PKR 53.27 | PKR 0.11/mL | 95% below median |
| ZATRIK (Low Osmolarity ORS) | Sodium chloride + Sodium citrate + Potassium chloride + Glucose | 1.3 g + 1.45 g + 0.75 g + 6.75 g | Sachet | 20's | 088203 | PKR 428.50 | PKR 21.43/sachet | No comparator |
| Zatron | Ceftazidime | 250 mg | Injection | 1 vial | 021811 | PKR 159.65 | PKR 159.65/vial/unit | Near median |
| Zatron | Ceftazidime | 500 mg | Injection | 1 vial | 021812 | PKR 242.83 | PKR 242.83/vial/unit | Near median |
| Zatron | Ceftazidime | 1 g | Injection | 1 vial | 021813 | PKR 456.12 | PKR 456.12/vial/unit | Near median |
| ZINGER | Ribavirin | 400 mg | Capsule | 1x10's | 023820 | PKR 572.45 | PKR 57.25/capsule | Near median |
| ZINGER | Ribavirin | 100 mg | Capsule | 1x10's | 026887 | PKR 267.76 | PKR 26.78/capsule | Near median |
| ZINGER | Ribavirin | 200 mg | Capsule | 1x10's | 026888 | PKR 406.26 | PKR 40.63/capsule | 15% below median |
| ZINGER | Ribavirin | 600 mg | Tablet | 1x10's | 027151 | PKR 914.07 | PKR 91.41/tablet | 274% above median |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.